Allen J. Duplantier

The Human Cathelicidin Antimicrobial Peptide LL-37 as a Potential Treatment for Polymicrobial Infected Wounds

Allen J. Duplantier, Monique L. van Hoek · Frontiers in Immunology · 2013 · 236 citations · Full text

Biarylcarboxylic Acids and -amides:  Inhibition of Phosphodiesterase Type IV versus [³H]Rolipram Binding Activity and Their Relationship to Emetic Behavior in the Ferret

Allen J. Duplantier, Michael S. Biggers, Robert Chambers et al. · Journal of Medicinal Chemistry · 1996 · 143 citations · Full text

Discovery, SAR, and Pharmacokinetics of a Novel 3-Hydroxyquinolin-2(1<i>H</i>)-one Series of Potent<scp>d</scp>-Amino Acid Oxidase (DAAO) Inhibitors

Allen J. Duplantier, Stacey L. Becker, Michael J. Bohanon et al. · Journal of Medicinal Chemistry · 2009 · 109 citations · Full text

Optimization of the physicochemical and pharmacokinetic attributes in a 6-azauracil series of P2X7 receptor antagonists leading to the discovery of the clinical candidate CE-224,535

Allen J. Duplantier, Mark A. Dombroski, Chakrapani Subramanyam et al. · Bioorganic & Medicinal Chemistry Letters · 2011 · 75 citations · Full text

Medicinal Chemistry, Clinical Candidate Ce-224,535, Biochemistry +9

Discovery of 4-(5-Methyloxazolo[4,5-<i>b</i>]pyridin-2-yl)-1,4-diazabicyclo[3.2.2]nonane (CP-810,123), a Novel α7 Nicotinic Acetylcholine Receptor Agonist for the Treatment of Cognitive Disorders in Schizophrenia: Synthesis, SAR Development, and in Vivo Efficacy in Cognition Models

Christopher J. O’Donnell, Bruce N. Rogers, Brian S. Bronk et al. · Journal of Medicinal Chemistry · 2009 · 73 citations · Full text